Device Trial Radar · NCT02766543
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Actual
Start
Sep 21, 2016
Primary completion
Feb 28, 2019
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Profound Medical Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 9, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.
Conditions
- Prostate Cancer
Interventions
MRI-guided Transurethral Ultrasound AblationDevice
Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Endpoint - Incidence of treatment-emergent adverse eventsTime frame: 1 year
1 more outcomes with a free account
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
13 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.